Company information

About Cathpax

Founded in 2024, Cathpax designs, develops and commercialises innovative, full-body, team-wide radiation protection systems for cath lab staff during interventional procedures. Spin-off of the Lemer Pax group, the company leverages more than 50 years of innovation in the radiation protection field. A pioneer in ionising radiation protection since the 1970s, Lemer Pax spent the past two decades developing groundbreaking innovations to advance its mission of Protecting Life® over the last two decades. The group has created cutting-edge radiation protection materials and technologies used in thousands of products worldwide. Today, Lemer Pax covers three major areas of expertise through three different entities: Lemer Pax (Civilian nuclear sector, radiopharmacy, nuclear medicine and radiology), GMP (therapy radioisotope production) and Cathpax (interventional medicine).

Developed over more than 10 years of research & development, Nova-X® is Cathpax’s second-generation radiation protection system. Protected by more than 10 patents, Nova-X® is currently the only available solution on the market providing 2 mm lead equivalence. The system features a unique dose monitoring system displaying real-time dose rate reduction (Dosicath®). Nova-X® also boasts a built-in laser system that projects two green laser beams onto the floor, clearly marking out a controlled zone for Healthcare providers (Laserguard®). Thanks to all these unique features, Nova X® drastically improves cath lab staff safety and comfort, promoting stress-free working conditions through efficient full-body and team-wide protection against radiation injuries, ultimately benefiting the patient.

Nova-X® received CE-Mark certification in 2025 and the company expects to obtain FDA approval over the course of the next two years. Based in Nantes, France, Cathpax aims to become the world leader in full-body, team-wide radiation protection in interventional medicine.

NEWS

JUN-2026

Commercial launch EN

JUN-2026

Commercial launch FR

JAN-2026

NOVARAD clinical results EN

JAN-2026

NOVARAD clinical results FR